LEADER 05809nam 22008055 450 001 9911049200503321 005 20260102122702.0 010 $a981-9514-26-6 024 7 $a10.1007/978-981-95-1426-7 035 $a(CKB)44769046600041 035 $a(MiAaPQ)EBC32470690 035 $a(Au-PeEL)EBL32470690 035 $a(DE-He213)978-981-95-1426-7 035 $a(EXLCZ)9944769046600041 100 $a20260102d2025 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPathogenesis, Management and Socio-Economic Impact of COVID-19 Pandemic /$fedited by Mrinal K. Ghosh, Malini Basu 205 $a1st ed. 2025. 210 1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2025. 215 $a1 online resource (689 pages) 225 1 $aMedical Virology: From Pathogenesis to Disease Control,$x2662-9828 311 08$a981-9514-25-8 327 $aPart 1 COVID-19 Pandemic: Pathogenesis, Inflammation, and Biology -- Ch 1 The COVID-19 Outbreak -- Ch 2 Pathogenesis and Biology of SARS-CoV-2 -- Ch 3 COVID-19: Modulation of Host?s Genetic and Epigenetic Machineries -- Ch 4 SARS-CoV-2 Mutants and Variants of Interest -- Part 2 COVID-19: Diagnosis and Development of Diagnostics -- Ch 5 Imaging-Based COVID-19 Diagnosis -- Ch 6 Nucleic Acid Amplification Testing (NAAT) based COVID-19 Kits -- Ch 7 Immunological Assay Based COVID-19 Detection -- Ch 8 Variant-Specific Diagnosis of COVID-19 -- Part 3 COVID-19: Immunological Perspectives -- Ch 9 Cytokine Storm, Inflammation, and Immunity in COVID-19 -- Ch 10 COVID-19: Modulation of Signaling Pathways -- Ch 11 Immunological Persistence and Risk of SARS-CoV-2 Re-infection: Insights and Implications -- Ch 12 Plasma Therapy in COVID-19 -- Part 4 COVID-19 Drug Repurposing: Mode of Action, Clinical Trials, and Future Perspectives -- Ch 13 Repurposing of Anti-viral Agents in COVID-19 -- Ch 14 Role of Anti-inflammatory Agents in the Management of COVID-19 -- Ch 15 Application of Anti-platelet Drugs and Anti-coagulants in COVID-19 -- Ch 16 COVID-19: Target-Based Drug Discovery -- Part 5 COVID-19: Vaccine Development and Vaccination -- Ch 17 COVID-19: Vaccine Classification and their Clinical Status -- Ch 18 SARS-CoV-2: A Comprehensive Insight into DNA, RNA, Subunit, and Viral Vaccines -- Ch 19 COVID-19 Vaccination in Medically Distinct Population -- Part 6 COVID-19 Associated Comorbidities, Economic and Societal Impact -- Ch 20 Neurological damages in COVID-19 patients -- Ch 21 COVID-19 Comorbidities in Cancer -- Ch 22 Interplay of COVID-19 with Tuberculosis and Pneumonia: Challenges and Treatment -- Ch 23 Economic Consequences of the COVID-19 Pandemic -- Ch 24 COVID-19 Pandemic and Its Societal Impact: A Philosophical/Theoretical Perspective in Human Quantum Mechanics -- Ch 25 Unravelling the Global Economic Impact: A Region and Sector-wise Post-COVID Analysis -- Ch 26 Navigating Long COVID: Comorbidities and the Global Societal Impact. 330 $aThis book provides up-to-date insights into the COVID-19 disease, addressing its outbreak, pathogenesis, biology, treatment interventions, and consequences as a global health crisis. Divided into six sections, the book covers a detailed examination of various facets of the disease. Section I delves into the host's genetic and epigenetic mechanisms in response to COVID-19. Section II focuses on disease diagnosis, providing valuable perspectives on kits, nucleic acid testing, immunological assays, imaging-based diagnosis, and variant-specific SARS-COV-2 detection. Section III covers cytokine storm, inflammation, and immunity, including the modulation of signaling pathways leading to immune evasion and persistence. Section IV reveals drug repurposing, exploring antiviral, anti-inflammatory, anti-platelet drugs, and target-based drug discovery. Section V explains the evolution of vaccine development including DNA, RNA, subunit, and viral vaccines. Finally, Section VI explores COVID-19's impact on associated comorbidities, ranging from cancer and cardiac issues to neurological damages and economic consequences. The book is relevant for scientists, and researchers working on pathogenesis, development, implementation, host-pathogen interactions, and drug repurposing of COVID-19 disease. 410 0$aMedical Virology: From Pathogenesis to Disease Control,$x2662-9828 606 $aVirology 606 $aMedical microbiology 606 $aPublic health 606 $aBiologicals 606 $aBiopharmaceutics 606 $aVaccines$xBiotechnology 606 $aBiomaterials 606 $aMedicine, Preventive 606 $aHealth promotion 606 $aVirology 606 $aMedical Microbiology 606 $aPublic Health 606 $aBiologics 606 $aBiomaterials-Vaccines 606 $aHealth Promotion and Disease Prevention 615 0$aVirology. 615 0$aMedical microbiology. 615 0$aPublic health. 615 0$aBiologicals. 615 0$aBiopharmaceutics. 615 0$aVaccines$xBiotechnology. 615 0$aBiomaterials. 615 0$aMedicine, Preventive. 615 0$aHealth promotion. 615 14$aVirology. 615 24$aMedical Microbiology. 615 24$aPublic Health. 615 24$aBiologics. 615 24$aBiomaterials-Vaccines. 615 24$aHealth Promotion and Disease Prevention. 676 $a579.2 676 $a616.96 700 $aGhosh$b Mrinal K$01885544 701 $aBasu$b Malini$01885545 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911049200503321 996 $aPathogenesis, Management and Socio-Economic Impact of COVID-19 Pandemic$94520823 997 $aUNINA